Merck has begun construction on a new $3 billion Center of Excellence for pharmaceutical manufacturing plant in Elkton, Virginia. The billion-dollar investment is aimed at advancing small-molecule production and strengthening the company’s U.S. manufacturing capabilities. The 400,000-square-foot facility will serve as a state-of-the-art hub for active pharmaceutical ingredient (API) and drug-product manufacturing.

The new $3 billion pharmaceutical manufacturing facility in Virginia will create over 500 full-time jobs once operational, in addition to generating roughly 8,000 construction jobs during the build-out phase. Located adjacent to Merck’s existing operations in Elkton, the new Center of Excellence will focus on developing next-generation production technologies and scaling up manufacturing for critical therapies. The investment is also part of Merck’s wider strategy to modernize and expand its U.S. manufacturing footprint amid growing global demand for pharmaceuticals and increasing emphasis on localized supply chains.

Project name: Merck Elkton Center of Excellence for Pharmaceutical Manufacturing

Location: Elkton, Virginia

Owner: Merck & Co., Inc.

Investment value: US$3 billion

Facility size: 400,000 sq ft

Focus: Advanced small-molecule pharmaceutical manufacturing

Jobs created: 500 full-time roles. 8,000 construction jobs

Partners: Supported by state and local agencies in Virginia

October 2025: Groundbreaking and official launch of construction.

2026-2027: Construction and equipment installation phases.

2028: Initial operations and validation of production lines expected.

2028 onward: Full commercial production ramp-up and integration into Merck’s U.S. manufacturing network.

The Elkton facility strengthens Virginia’s position as an emerging hub for advanced pharmaceutical manufacturing. State officials have also emphasized the project’s importance in driving high-skilled job creation and boosting local economic activity.

Nationally, it aligns with U.S. efforts to secure domestic drug manufacturing and reduce dependency on overseas production.

For Merck, the expansion also supports both strategic growth and operational flexibility as the company continues to scale production for key therapies and pipeline products.

Merck’s new Elkton Center of Excellence forms part of a broader, multi-billion-dollar modernization program across its U.S. operations. In recent years, the company has expanded several strategic sites. This includes its vaccine manufacturing facilities in Durham, North Carolina, and West Point, Pennsylvania. The American multinational pharmaceutical company also began construction on a $1 billion biologics manufacturing facility in Wilmington, Delaware earlier this year.

In Durham, Merck invested over $1 billion to scale up manufacturing for key vaccines and biologics, focusing on high-efficiency production systems and digital process control. Meanwhile, its West Point site has been undergoing a major capacity expansion, integrating automation and sustainable design to support global supply for a range of products.

Compared to these expansions, the Elkton facility represents Merck’s most significant U.S. investment dedicated specifically to small-molecule pharmaceutical manufacturing. The site is positioned to serve as a flagship for next-generation drug production technologies, complementing the company’s biologics and vaccine operations elsewhere.